Add to Calendar 9/9/2019 10:00:00 AM 9/9/2019 5:00:00 PM Digital Health Impact 2019

Online registration is now closed, there will be a limited number of onsite registrations on Monday

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, reshaping clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for our inaugural Digital Health Impact 2019 event at the InterContinental Boston at 510 Atlantic Ave, Boston, MA 02210, part of Biotech Week Boston, as we examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, we’ll explore new strategies for life sciences and digital health innovators to converge and ultimately deliver better outcomes for patients. Contact Laura Rudberg for sponsorship opportunities. View our sponsorship prospectus here. 

 Intercontinental Boston, 510 Atlantic Avenue, Boston MA, 02210
Managing Partner, Binney Street Capital, CEO, Kojin Therapeutics Senior Lecturer, Harvard University
Luba is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. She is also the CEO of one of BSC’s portfolio companies Kojin Therapeutics, which is discovering and developing novel therapeutics in oncology, fibrosis, and immune modulation. She is a professor at Harvard University in the School of Engineering and Applied Sciences. Luba has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub. Luba has led $5B+ in deals and investments across multiple therapeutic areas and life sciences and tech sectors globally. She has also co-founded biotech and digital health companies in the immunotherapy, AI/ML, women's health and microbiome space, including Luca Biologics. She has served on multiple public, private, and non-profit boards, including the Massachusetts Biotechnology Council (MassBio), Kojin Tx, Brooklyn ImmunoTherapeutics, BenchSci, In8Bio, and OS Fund, a SPAC. She has advised leading academic centers globally including the CEO of the Dana-Farber Cancer Institute as well as the Director of the Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute. Luba is also a former litigator and regulatory, policy, and IP expert, having started her career at Wilmer Cutler Pickering Hale and Dorr. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.

Brought to you by